Biblio
Found 230 results
Author Keyword [ Title] Type Year Filters: First Letter Of Last Name is K [Clear All Filters]
“Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.”, Nat Genet, vol. 43, no. 5, pp. 429-35, 2011.
, “Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.”, Nat Genet, vol. 43, no. 5, pp. 429-35, 2011.
, “Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.”, Nat Genet, vol. 43, no. 5, pp. 429-35, 2011.
, “Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.”, Nat Genet, vol. 43, no. 5, pp. 429-35, 2011.
, “Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.”, Nat Genet, vol. 43, no. 5, pp. 429-35, 2011.
, “A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease.”, Nat Neurosci, vol. 20, no. 8, pp. 1052-1061, 2017.
, “A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease.”, Nat Neurosci, vol. 20, no. 8, pp. 1052-1061, 2017.
, “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.”, Neurology, vol. 34, no. 7, pp. 939-44, 1984.
, “Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants.”, PLoS Genet, vol. 8, no. 6, p. e1002707, 2012.
, “Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants.”, PLoS Genet, vol. 8, no. 6, p. e1002707, 2012.
, “Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme.”, Am J Med Genet B Neuropsychiatr Genet, vol. 136B, no. 1, pp. 62-8, 2005.
, “Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.”, Alzheimers Res Ther, vol. 6, no. 4, p. 39, 2014.
, “Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.”, Alzheimers Res Ther, vol. 6, no. 4, p. 39, 2014.
, “Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.”, Alzheimers Res Ther, vol. 6, no. 4, p. 39, 2014.
, “Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.”, Alzheimers Res Ther, vol. 6, no. 4, p. 39, 2014.
, “Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals.”, JAMA Neurol, vol. 72, no. 11, pp. 1313-23, 2015.
, “Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals.”, JAMA Neurol, vol. 72, no. 11, pp. 1313-23, 2015.
, “Apolipoprotein E in Alzheimer's disease risk and case detection: a case-control study.”, J Clin Epidemiol, vol. 49, no. 10, pp. 1143-8, 1996.
, “Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease.”, PLoS Genet, vol. 13, no. 11, p. e1007045, 2017.
, “Analysis of European mitochondrial haplogroups with Alzheimer disease risk.”, Neurosci Lett, vol. 365, no. 1, pp. 28-32, 2004.
, “Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals.”, PLoS One, vol. 7, no. 12, p. e50640, 2012.
, “The Alzheimer's Disease Sequencing Project: Study design and sample selection.”, Neurol Genet, vol. 3, no. 5, p. e194, 2017.
, “Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci.”, PLoS One, vol. 11, no. 2, p. e0148717, 2016.
, “Alzheimer's disease genetics: from the bench to the clinic.”, Neuron, vol. 83, no. 1, pp. 11-26, 2014.
, “Alzheimer's disease: analyzing the missing heritability.”, PLoS One, vol. 8, no. 11, p. e79771, 2013.
,